WallStreetZenWallStreetZen

NASDAQ: ATRA
Atara Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ATRA

Based on 5 analysts offering 12 month price targets for Atara Biotherapeutics Inc.
Min Forecast
$20.00+1,198.7%
Avg Forecast
$25.60+1,562.34%
Max Forecast
$31.00+1,912.99%

Should I buy or sell ATRA stock?

Based on 5 analysts offering ratings for Atara Biotherapeutics Inc.
Strong Buy
Strong Buy
4 analysts 80%
Buy
1 analysts 20%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ATRA stock forecasts and price targets.

ATRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Canaccord Genuity
Top 41%
60
Strong BuyMaintains$20.00+1,198.70%2023-05-09
EF Hutton
Bottom 22%
22
Strong BuyReiterates$25.00+1,523.38%2023-02-09
HC Wainwright & Co.
Bottom 1%
1
BuyMaintains$27.00+1,653.25%2023-02-09
Mizuho
Bottom 6%
6
Strong BuyReiterates$31.00+1,912.99%2023-02-07
EF Hutton
Bottom 4%
4
Strong BuyInitiates Coverage On$25.00+1,523.38%2023-01-05

1 of 1

Forecast return on equity

Is ATRA forecast to generate an efficient return?
Company
N/A
Industry
0.1%
Market
71.96%

Forecast return on assets

Is ATRA forecast to generate an efficient return on assets?
Company
N/A
Industry
0.12%

ATRA revenue growth forecast

How is ATRA forecast to perform vs Biotechnology companies and vs the US market?
Company
78.28%
Industry
40.04%
Market
8.43%
ATRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ATRA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ATRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ATRA$1.54$25.60+1,562.34%Strong Buy
INO$0.58$2.00+245.42%Hold
CRVS$3.20$5.83+82.28%Strong Buy
PRQR$1.89$5.13+171.16%Strong Buy
YS$1.50N/AN/A
View Top Biotech Stocks

Atara Biotherapeutics Stock Forecast FAQ

Is Atara Biotherapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ATRA) stock is to Strong Buy ATRA stock.

Out of 5 analysts, 4 (80%) are recommending ATRA as a Strong Buy, 1 (20%) are recommending ATRA as a Buy, 0 (0%) are recommending ATRA as a Hold, 0 (0%) are recommending ATRA as a Sell, and 0 (0%) are recommending ATRA as a Strong Sell.

If you're new to stock investing, here's how to buy Atara Biotherapeutics stock.

What is ATRA's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: ATRA) forecast ROE is N/A, which is considered weak.

What is ATRA's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ATRA price target, the average ATRA price target is $25.60, with the highest ATRA stock price forecast at $31.00 and the lowest ATRA stock price forecast at $20.00.

On average, Wall Street analysts predict that Atara Biotherapeutics's share price could reach $25.60 by May 9, 2024. The average Atara Biotherapeutics stock price prediction forecasts a potential upside of 1,562.34% from the current ATRA share price of $1.54.

What is ATRA's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: ATRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.12%.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.